NeuroBo Pharmaceuticals I... (NRBO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
2.36
0.01 (0.43%)
At close: Nov 27, 2024, 9:00 PM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 28.00K | 72.00K | 67.00K | 17.00K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -28.00K | -72.00K | -67.00K | -17.00K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -15.89M | -19.63M | -15.30M | -29.72M | -20.18M | -22.80M | -33.12M | -14.70M | -8.08M | -266.00K |
Interest Income | 461.00K | 2.19K | 14.00K | 39.00K | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -12.47M | -13.97M | -15.28M | -29.68M | -21.31M | -23.64M | -33.41M | -14.59M | -9.03M | -320.00K |
Net Income | -12.47M | -6.12M | -15.22M | -29.59M | -22.43M | -23.64M | -33.41M | -14.59M | -9.03M | -320.00K |
Selling & General & Admin | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 10.44M | 5.96M | 3.18M | 214.00K |
Research & Development | 9.16M | 2.78M | 6.55M | 21.87M | 17.48M | 14.31M | 22.69M | 8.74M | 3.99M | 52.00K |
Other Expenses | n/a | -83.00K | n/a | -1K | 12.15M | -178.00K | 10.44M | n/a | n/a | n/a |
Operating Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.80M | 33.12M | 14.70M | 7.17M | 266.00K |
Interest Expense | n/a | 2.19M | n/a | 39.00K | 22.00K | 654.00K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 10.38M | n/a | n/a | n/a |
Cost & Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.80M | 33.12M | 14.70M | 7.17M | 266.00K |
Income Tax | n/a | -7.85M | -62.00K | -85.00K | 1.12M | 654.00K | 286.00K | -136.82K | -146.00K | 55.00K |
Shares Outstanding (Basic) | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
Shares Outstanding (Diluted) | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
EPS (Basic) | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.8 | -2.42K | -1.88K | -1.28K | -45.27 |
EPS (Diluted) | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.8 | -2.42K | -1.88K | -1.28K | -45.27 |
EBITDA | -15.88M | -11.40M | -15.21M | -29.61M | -21.17M | -15.49M | -33.09M | -14.50M | -6.07M | -283.00K |
Depreciation & Amortization | 7.00K | 28.00K | 72.00K | 67.00K | 17.00K | 6.67M | 60.00K | -17.00K | 2.01M | -1K |